Navigation Links
Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Researchers from the University of Cincinnati presented results from a prospective study at the American Roentgen Ray Society 2011 Annual Meeting today, demonstrating how PEM-guided biopsy may expedite pre-operative work-up and reduce radiation exposure for breast cancer patients.  

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment.  Naviscan's Stereo Navigator® Accessory is the first ever commercialized PET-guided biopsy tool and has been FDA-cleared since 2008.

"PEM is useful for performing local staging in women with newly diagnosed breast cancer," stated Dr. Amy Argus, Assistant Professor of Radiology and one of the lead investigators of the study. "When additional breast abnormalities are identified by PEM, accurate PEM-guided biopsy can be performed on the same day as the diagnostic imaging, which decreases the patient's radiation dose and may expedite their preoperative work-up."

In this study, 18 women with breast cancer classified as BIRADS 5 identified on mammography or ultrasound underwent a PEM scan and same day PEM-guided biopsy on 24 index and satellite lesions.  Lesion size was 4-60 mm with a mean size of 16 mm.  Results were concordant for 83% of lesions and discordant for the remaining due to patient movement and operator experience.  PEM is the only technology where physicians are able to biopsy on the same injection of the radiotracer.  This is because the radiotracer utilized, FDG, does not washout of the tumor as with other blood flow-dependant modalities like MRI or BSGI.  By avoiding a double injection of radiotracer, the radiation exposure to the patient and medical personnel is reduced.  Same day procedures are also feasible with PEM given the ease of interpretation compared to other advanced imaging modalities.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit

SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
2. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
3. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
4. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
5. Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration
6. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
8. New Study Finds Individuals Who Adhere to Their Diabetes Medication Have a 31% Associated Lower Risk of Hospitalization
9. For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
10. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
11. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015  Strengthening its leadership ... PHG, AEX: PHIA) today announced IntelliSpace Portal 8.0 ... analytics and visualization platform that helps radiologists detect, diagnose ... 2015 Radiological Society of North America Annual Meeting ... IntelliSpace Portal 8.0 helps address the changing demands in ...
(Date:11/29/2015)... , Nov. 29, 2015  At this year,s ... to experience the most complete mobile C-arm portfolio with ... is Ziehm Vision RFD 3D, the world,s only 3D ... edge length per scan volume. In addition, Ziehm Imaging ... motorized mobile C-arm in four axes which is ideally ...
(Date:11/29/2015)... 29, 2015 CIVCO Medical Solutions will ... the Radiological Society of North America ... November 29 – December 4, 2015. ... offer customers unrivaled versatility, enhanced user experience and ... --> ...
Breaking Medicine Technology:
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Association of Poison Control Centers’ National Poison Data System (NPDS) reveals that in ... managed almost 3 million cases, over two million of which were human exposure ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage ... effective immediately. , “We are pleased to announce our expanded distribution agreement ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Solutions, announced at the Radiology Society of North America (RSNA) annual meeting, being ... over 60% growth from 2014. Throughout 2015, the company has completed installations ...
(Date:11/30/2015)... ... 30, 2015 , ... Holcomb – Kreithen Plastic Surgery ... practices in Florida, is proud to announce that Dr. Joshua Kreithen, one of ... Inc., a Johnson & Johnson Company. , Ethicon is a global medical device ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. and Novus ... technology for soft tissue repair in the US via Insightra’s national direct sales ... mesh intended to support and reinforce soft tissue for 6-9 months before absorbing ...
Breaking Medicine News(10 mins):